Literature DB >> 26244818

Nanoparticle-mediated drug delivery for treating melanoma.

Vaibhav Mundra1, Wei Li2, Ram I Mahato1.   

Abstract

Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10%, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.

Entities:  

Keywords:  active targeting; metastatic melanoma; multidrug resistance; nanoparticles; photodynamic therapy; polymer–drug conjugate; tumor initiating cells

Mesh:

Substances:

Year:  2015        PMID: 26244818      PMCID: PMC4624329          DOI: 10.2217/nnm.15.111

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  204 in total

1.  Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine.

Authors:  Jubo Liu; Yuehua Xiao; Christine Allen
Journal:  J Pharm Sci       Date:  2004-01       Impact factor: 3.534

2.  Human melanoma targeting with alpha-MSH-melphalan conjugate.

Authors:  G E Ghanem; A Libert; R Arnould; A Vercammen; F Lejeune
Journal:  Melanoma Res       Date:  1991 Jun-Jul       Impact factor: 3.599

3.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

4.  Hydrotropic solubilization of poorly water-soluble drugs.

Authors:  Ji Young Kim; Sungwon Kim; Michelle Papp; Kinam Park; Rodolfo Pinal
Journal:  J Pharm Sci       Date:  2010-09       Impact factor: 3.534

5.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

Authors:  J M Meerum Terwogt; W W ten Bokkel Huinink; J H Schellens; M Schot; I A Mandjes; M G Zurlo; M Rocchetti; H Rosing; F J Koopman; J H Beijnen
Journal:  Anticancer Drugs       Date:  2001-04       Impact factor: 2.248

6.  Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer.

Authors:  H S Yoo; T G Park
Journal:  J Control Release       Date:  2001-01-29       Impact factor: 9.776

7.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.

Authors:  Suzie H Pun; Frederik Tack; Nathalie C Bellocq; Jianjun Cheng; Brendan H Grubbs; Gregory S Jensen; Mark E Davis; Marcus Brewster; Michel Janicot; Boudewijn Janssens; Wim Floren; Annette Bakker
Journal:  Cancer Biol Ther       Date:  2004-07-09       Impact factor: 4.742

8.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics.

Authors:  Jihua Liu; Hillevi Bauer; Jon Callahan; Pavla Kopecková; Huaizhong Pan; Jindrich Kopecek
Journal:  J Control Release       Date:  2010-01-04       Impact factor: 9.776

10.  Does a targeting ligand influence nanoparticle tumor localization or uptake?

Authors:  Kathleen F Pirollo; Esther H Chang
Journal:  Trends Biotechnol       Date:  2008-08-21       Impact factor: 19.536

View more
  7 in total

1.  Microradiopharmaceutical for Metastatic Melanoma.

Authors:  Thiago Goulart Rosa; Sofia Nascimento Dos Santos; Terezina de Jesus Andreoli Pinto; Daniele Dal Molim Ghisleni; Thereza Christina Barja-Fidalgo; Eduardo Ricci-Junior; Mohammed Al-Qahtani; Jan Kozempel; Emerson Soares Bernardes; Ralph Santos-Oliveira
Journal:  Pharm Res       Date:  2017-10-23       Impact factor: 4.200

2.  Emerging concepts of T cell metabolism as a target of immunotherapy.

Authors:  Chih-Hao Chang; Erika L Pearce
Journal:  Nat Immunol       Date:  2016-04       Impact factor: 25.606

Review 3.  Advances in Carbon Nanotubes for Malignant Melanoma: A Chance for Treatment.

Authors:  Elidamar Nunes de Carvalho Lima; José Roberto Castilho Piqueira; Durvanei Augusto Maria
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

4.  Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part II: In vitro and in vivo Kinetics Study.

Authors:  Aya Ahmed Sebak; Iman Emam Omar Gomaa; Aliaa Nabil ElMeshad; Mahmoud Hussien Farag; Ulrike Breitinger; Hans-Georg Breitinger; Mahmoud Hashem AbdelKader
Journal:  Int J Nanomedicine       Date:  2020-11-30

5.  Theranostic barcoded nanoparticles for personalized cancer medicine.

Authors:  Zvi Yaari; Dana da Silva; Assaf Zinger; Evgeniya Goldman; Ashima Kajal; Rafi Tshuva; Efrat Barak; Nitsan Dahan; Dov Hershkovitz; Mor Goldfeder; Janna Shainsky Roitman; Avi Schroeder
Journal:  Nat Commun       Date:  2016-11-10       Impact factor: 14.919

6.  Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.

Authors:  Tian Zhang; Preethy Prasad; Ping Cai; Chunsheng He; Dan Shan; Andrew Michael Rauth; Xiao Yu Wu
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

Review 7.  Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.